Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
181-195 of 355
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
MinuteCE®Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Hussein Tawbi, MD, PhD
Sapna Patel, MD
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
MinuteCE®Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Hussein Tawbi, MD, PhD
Sapna Patel, MD
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
MinuteCE®Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Paolo A. Ascierto, MD
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
CME/CEADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
Reshma L. Mahtani, DO
- advertisement
Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML
MinuteCE®Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML
Ghayas Issa, MD
Amir Fathi, MD
Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management
MinuteCE®Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management
Ghayas Issa, MD
Amir Fathi, MD
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
CME/CECommunity Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
Robert J. Motzer, MD
Elizabeth R. Plimack, MD, MS, FASCO
Ghayas Issa, MD
Amir Fathi, MD
Ongoing Clinical Trials in AML With Menin Inhibitors
MinuteCE®Ongoing Clinical Trials in AML With Menin Inhibitors
Ghayas Issa, MD
Amir Fathi, MD
Managing Adverse Events Associated With Menin Inhibitors
MinuteCE®Managing Adverse Events Associated With Menin Inhibitors
Ghayas Issa, MD
Amir Fathi, MD
- advertisement
Emerging Directions in Menin-Directed AML Therapy
MinuteCE®Emerging Directions in Menin-Directed AML Therapy
Ghayas Issa, MD
Amir Fathi, MD
Ghayas Issa, MD
Amir Fathi, MD
Ghayas Issa, MD
Amir Fathi, MD
